SMARCA2 and cancer: The increased sensitivity of BRG1-LOF tumors to degraders or inhibitors of SMARCA2, aurora kinase, CDK4/6, oxidative phosphorylation, and other survival factors demonstrates the broad therapeutic vulnerabilities of these cancers [25,26,27,28,29,30].